Eversept Partners LP acquired a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 5,391,548 shares of the company’s stock, valued at approximately $12,670,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Commodore Capital LP bought a new position in Palisade Bio during the fourth quarter valued at approximately $26,896,000. Artia Global Partners LP bought a new position in Palisade Bio during the fourth quarter valued at approximately $4,682,000. Balyasny Asset Management L.P. bought a new position in Palisade Bio during the fourth quarter valued at approximately $765,000. Boothbay Fund Management LLC bought a new position in Palisade Bio during the fourth quarter valued at approximately $312,000. Finally, ACT Capital Management LLC bought a new position in Palisade Bio during the fourth quarter valued at approximately $352,000. Institutional investors own 11.79% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on PALI shares. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings lowered shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. HC Wainwright assumed coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Wolfe Research assumed coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.20.
Palisade Bio Trading Down 1.1%
Shares of PALI stock opened at $1.76 on Thursday. Palisade Bio, Inc. has a 1 year low of $0.53 and a 1 year high of $2.86. The firm’s fifty day simple moving average is $1.97 and its 200 day simple moving average is $1.90. The firm has a market capitalization of $305.50 million, a P/E ratio of -1.74 and a beta of 1.52.
Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Equities research analysts anticipate that Palisade Bio, Inc. will post -0.21 EPS for the current fiscal year.
Palisade Bio Company Profile
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
See Also
- Five stocks we like better than Palisade Bio
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding PALI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palisade Bio, Inc. (NASDAQ:PALI – Free Report).
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
